Psoriasis is a common, chronic inflammatory dermatosis, and patients with psoriasis often develop nail involvement. It is ...

In the assessment of 12-month price targets, analysts unveil insights for Arcutis Biotherapeutics, presenting an average ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Kanji, an age-old fermented beverage made from carrots, mustard seeds, and spices, offers numerous health benefits including ...

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

Psoriasis is more than just a skin condition – it’s an autoimmune disorder that can manifest as scales, spots, or even ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about ...

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.